Our People
SCOTT GRIFFITH
JESSE SHELMIRE
PRESTON GRAHAM
DAVE STORMS, CFA
ZACH AMREIN
SHIV S. KAPOOR
JUSTIN MARTIN
EROL GIRGIN
JOHN JANES
QUENTIN HARRAH
BEN DOSSETT
ROBIN AGIR
TOM BAKER
DENNIS DOBSON
ALAMGIR SINGH KANDHARI
AN TRAN
SCOTT GRIFFITH
Co-CEO, Partner
Stonegate Capital Partners
Scott joined Stonegate in 1992 and is a co-owner of Stonegate. Prior to joining Stonegate, Scott was a Vice-President at Donaldson, Lufkin, & Jenrette from 1980 to 1988 and a Vice-President at Smith Barney from 1988 to 1992. He received his Bachelor of Science in Marketing from Florida State University in 1979. Scott is licensed with Stonegate Capital Markets and currently holds FINRA Series 7, 14, 24, 63, 79, 99 licenses.
JESSE SHELMIRE
Co-CEO, Partner
Stonegate Capital Partners
Jesse is Co-CEO/Partner of Stonegate Capital Partners/Stonegate Capital Markets(Member FINRA/SIPC), and a Co-Founder of Stonegate Healthcare Partners. Jesse spent the first decade of his investment career in 1981 at Smith Barney in retail sales and then later at Jefferies in institutional sales. In the mid-90’s, Jesse was the Managing Director of Investment Banking for First London Securities where he managed public and private transactions. In 1999, Jesse joined Stonegate where he’s managed ~100 transactions and currently provides advisory services for both public and private companies with a focus on healthcare. Jesse received his Bachelor of Science in Economics in 1979 from The Wharton School of Business at the University of Pennsylvania. Jesse is licensed with Stonegate Capital Markets and currently holds FINRA Series 7,24, 63, 79, 99 licenses.
PRESTON GRAHAM
Partner
Stonegate Capital Partners
Preston is the Head of Institutional Sales. He joined Stonegate in 2010. His primary responsibilities involve managing the sales desk, overseeing our institutional outreach effort, and advising issuers on capital markets strategy. Preston was previously with Howard Financial Services in Dallas. He graduated from Santa Clara University with a degree in finance. Preston is licensed with Stonegate Capital Markets, Inc. and currently holds FINRA Series 7, 63, 79, and 99 licenses.
DAVE STORMS, CFA
Director of Research
Stonegate Capital Markets
Dave joined Stonegate in 2022. He was most recently an equity research analyst at Goldman Sachs. He was formerly a Senior investment analyst at Beneficial Financial Group, an analyst at Valuation Research Corporation, and an investment analyst with The Board of Pensions (PCUSA) focused on public equities. He started his career at Vanguard after receiving his undergraduate degree from Rowan University and a Masters in investment management from Temple University. David is licensed with Stonegate Capital Markets and currently holds FINRA Series SIE, 7, 87.
ZACH AMREIN
Managing Director
Business Development & CFO
Zach is a managing director of business development and our CFO. He joined Stonegate in 2016. He formerly worked in Finance at Legacy Housing. He graduated from the University of Kansas with degrees in Finance and Accounting.
SHIV S. KAPOOR
Co-Founder, Stonegate Healthcare
Shiv is a Co-Founder of Stonegate Healthcare and is a biotech veteran with over 25 years of experience in investments and the development of Oncology therapeutics. He has been rated among the top three biotechnology analysts by Forbes in the US. Shiv ran the Smith Barney Biotech fund at Citigroup and started Sellside Biotech practices at Montgomery & Co. and Morgan Joseph. His opinion on the US Biotechnology sector has been widely quoted in leading US media including CNN, CNBC, Bloomberg, and Barron’s Guide. In the past decade, Shiv led investor relations and corporate strategy at Spectrum pharmaceuticals. In 2020 he founded BioRamon Pharmaceuticals, a biopharmaceutical company involved in early discovery and research of oncology medicine. Shiv has a BA in Biochemistry from UC Berkeley and an MBA from the University of Chicago Booth School of Business.
JUSTIN MARTIN
Managing Director,
Institutional Sales & ESG Advisory
Justin is a managing director and helps lead the institutional sales effort. He also advises issuers on ESG rating policies and best practices. He joined Stonegate in 2012 and graduated from Auburn University with a Bachelor of Science in Finance. Justin is licensed with Stonegate Capital Markets, Inc. and currently holds FINRA Series 7, 63, and 79 licenses.
EROL GIRGIN
VP, Institutional Sales
Erol is a Vice President. He Joined Stonegate in 2021. He graduated from Texas Christian University with a Bachelor of Science in economics, and a minor in business. He is currently an MBA Candidate at the University of the Cumberlands.
JOHN JANES
VP, Institutional Sales & Research
John is a Vice President. He joined Stonegate in 2020 and primarily assists clients with institutional investor outreach and is also part of the equity research team. He graduated from Southern Methodist University with a Bachelor of Science in Economics with Finance Applications and a Minor in Advertising. John is licensed with Stonegate Capital Markets, Inc. and currently holds FINRA Series 7 and 63 licenses.
QUENTIN HARRAH
Senior Associate, Institutional Sales
Quentin is a Senior Associate. He joined Stonegate in 2021. He graduated from Louisiana State University with degrees in marketing and professional sales.
BEN DOSSETT
Associate, Institutional Sales
Ben is an Institutional Sales Associate. He joined Stonegate in 2022. He graduated from the University of Alabama with a Bachelor of Science in general business with a sales certificate. He was formerly with Liberty Mutual Insurance.
ROBIN AGIR
Associate, Institutional Sales
Robin is an institutional sales associate. He joined Stonegate in 2022. He was formerly with SRG Capital Partners. He graduated from The University of North Texas with a degree in marketing and communications.
TOM BAKER
Advisor, PR Technology & Competitive Surveillance
Tom is the CEO and cofounder of Reportable, a corporate communications and competitive intelligence software and service. Reportable is helping companies across all industries ranging from top venture-backed startups to publicly traded Fortune 500 companies. Tom has more than 20 years of experience working in corporate communications and investor relations for biotech and medical device companies. Tom graduated UCSD with a B.S. in Pharmacological Chemistry. An avid surfer, Tom grew up in San Diego and currently lives in the Boston area with his wife Melissa and 3 young boys.
DENNIS DOBSON
Managing Director, PR Outreach
Dennis has been a member of the healthcare and technology Public Relations and Investor Relations community for more than three decades and has developed results-oriented programs for a variety of healthcare and technology companies. He has managed highly successful media outreach programs including product launches and financial communications for biotechnology, digital technology, pharmaceutical, medical device, and healthcare services businesses at all stages of their lifecycles. His marketing communications, corporate identity and related brand-development activities have enabled him to serve as a private consultant to start-up and early-stage life science companies. Dennis has a master’s degree in Media Studies from The New School For Social Research in New York City, and a BA from The City University of New York, Baruch College.
ALAMGIR SINGH KANDHARI
Research Analyst
Stonegate Healthcare
Alamgir is a Research Analyst at Stonegate Healthcare and has a BA in Biology from UC Santa Cruz and a Master of Biotechnology & Stem Cell Science from San Jose State University. At UCSC, Alamgir did research in the Sanford Lab to better understand aberrant pre-mRNA splicing mechanisms causing genetic diseases. At BioMarin Pharmaceuticals, he ran cell culture and protein purification GMP production processes. Prior to his role at Stonegate, Alamgir worked at Notable labs, an immuno-oncology company, to develop the ex-vivo assay platform allowing Notable to target Leukemia Stem Cells in AML. He has experience in scientific writing, presenting, experimental, GMP production, and project management. Concurrently he is leading business development at BioRamon Pharmaceuticals to in license and develop oncology drugs.
Securities offered through Stonegate Capital Markets, Inc. (Member FINRA – SIPC)